Climb Bio, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 20 WILLIAM STREET, WELLESLEY HILLS, MA, 02481
Mailing Address 20 WILLIAM STREET, WELLESLEY HILLS, MA, 02481
Phone 1-866-857-2596
Fiscal Year End 1231
EIN 832273741
Financial Overview
FY2025
$211.88M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 10-K Annual financial report | March 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 4 Insider stock transaction report | January 8, 2026 | View on SEC |
| 8-K Current report of material events | January 8, 2026 | View on SEC |
Annual Reports
10-K March 5, 2026
- CLYM-101, a novel gene therapy for SMA, successfully completed Phase 1 and advanced to a multi-center Phase 2 clinical trial in Q4 2025.
- Expanded preclinical pipeline with two new gene therapy candidates, CLYM-202 (Huntington's Disease) and CLYM-303 (ALS), showing promising animal study results.
Material Events
8-K Legal Issue December 31, 2025
High Impact
- Climb Bio, Inc. filed a lawsuit against Alumis Inc. and its subsidiary Acelyrin, Inc.
- The lawsuit seeks a court declaration that Climb Bio does not owe a milestone payment related to the drug 'budoprutug'.
Insider Trading
SELL 2 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.